South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Purpose: Pirfenidone and nintedanib are two novel antifibrotic agents licensed for the treatment IPF. Prior to being approved for use in England for patients with FVC >50% and <80%, these were made available for all IPF patients under the Mild Patient Program (MPP) and Patient In Need...

Full description

Bibliographic Details
Main Authors: Shaney L. Barratt, Sarah Mulholland, Khaled Al Jbour, Henry Steer, Markus Gutsche, Noeleen Foley, Rajiv Srivastava, Charles Sharp, Huzaifa I. Adamali
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-12-01
Series:Frontiers in Pharmacology
Subjects:
idiopathic pulmonary fibrosis
anti-fibrotic medications
nintedanib
pirfenidone
interstitial lung disease
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.01480/full

Similar Items

Similar Items